Both hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are characterized by thrombotic microangiopathy (TMA), affecting mainly the kidney and brain, respectively. Diagnosis ...

Atypical hemolytic–uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain normal levels ...

Left untreated, PNH could cause death in about half of patients within 10 years of diagnosis. The primary cause of PNH-related mortality is thromboembolic events. A host of anti-complement strategies, ...

Patients who are taking complement inhibitors may still experience breakthrough hemolysis associated with respiratory viral infections. Patients with PNH should be closely monitored for signs of ...

An 18-month-old boy was admitted with a fourth relapse of congenital atypical hemolytic–uremic syndrome. He was born at 34 weeks' gestation, and thrombotic microangiopathy developed within the first 8 ...

Alnylam Scientists Present Pre-clinical Data with ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases – New Research Presented at 6 th ...

Please provide your email address to receive an email when new articles are posted on . The monoclonal antibody eculizumab has received accelerated approval from the FDA for the treatment of pediatric ...